Bipolar disorder and schizophrenia are serious mental illnesses that typically present during the college-age years.The prevalence of mental illness is increasing, particularly in the young adult.The onset of bipolar disorder and schizophrenia during the college-age years and the poor outcome associated with unrecognized illness underscore the need for early diagnosis and treatment in this population.
Educational Overview
Bipolar disorder and schizophrenia are serious mental illnesses that typically present during the college-age years.The prevalence of mental illness is increasing, particularly in the young adult.The onset of bipolar disorder and schizophrenia during the college-age years and the poor outcome associated with unrecognized illness underscore the need for early diagnosis and treatment in this population.
Target Audience
Psychiatrists and other health care professionals interested in learning about the identification, treatment, and management of college students with bipolar disorder and schizophrenia in the campus environment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the prevalence and disease onset characteristics of bipolar disorder and schizophrenia in college-aged students
- Describe the potential long-term outcomes forpatients with bipolar disorder and schizophrenia who have a family history of mental health disorders or who have prolonged undiagnosed disease
- Identify clinical indicators of bipolar disorder and schizophrenia in college-aged students
- Review common comorbidities of bipolar disorder and schizophrenia, including potential misdiagnoses
- Discuss appropriate methods of diagnosing college students with bipolar disorder and schizophrenia
Accreditation Statement
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
Certification Statement
Temple University School of Medicine designates this educational activity for a maximum of 1 AMA Physician's Recognition Award Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure Policy
It is the policy of Temple University School of Medicine, The Albert J. Finestone, MD Office for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).
The information presented in this CME program represents the views and opinions of the individual presenters and does not constitute the opinion or endorsement of, or promotion by,Temple University School of Medicine,Temple University Health System, or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements.However, each program participant must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including, without limitation,FDA-approved uses and any off-label uses.
Faculty Disclosure Declarations
Paul P. Doghramji, MD, FAAFP, has been a consultant for Takeda Pharmaceutical Company Ltd; Cephalon, Inc; and Wyeth Pharmaceuticals. He is a member of the speakers bureau for Takeda Pharmaceutical Company Ltd; Cephalon, Inc; sanofi-aventis; Sepracor Inc; and Pfizer Inc.
Theresa R. Cerulli, MD, is a member of the speakers bureau for Shire Pharmaceuticals and Novartis Pharmaceuticals Corporation.
Kristine A. Girard, MD, has no relationships with commercial entities related to the health care industry to disclose.
Barry A. Schreier, PhD, has no relationships with
commercial entities related to the health care industry
to disclose.
All faculty and planning committee members have submitted a disclosure form. Those with something to disclose are listed. All efforts have been made to resolve these conflicts based on the guidelines outlined by the ACCME and the policies and procedures of Temple University School of Medicine.